BioNTech and partner DualityBio are accelerating the development of their B7-H3 antibody-drug conjugate into a phase 3 trial for metastatic castration-resistant prostate cancer (mCRPC). | BioNTech and ...
India faces a growing crisis in wound treatment, driven by diabetes and an ageing population. A new policy approach could ...
Wave, marked by positive clinical data sets in obesity and AATD that further demonstrated the broad potential of our unique ...
Trump Orders Government to Stop Using Anthropic After Pentagon Standoff The company had clashed with the military over how officials wanted to use its A.I. model. The order could complicate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results